MAPK, β-amyloid and synaptic dysfunction: the role of RAGE

References

• Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest.115(5), 1121–1129 (2005).
   PubMed Web of Science ®Google Scholar
• Kametani F. ε-secretase: reduction of amyloid precursor protein ε-site cleavage in Alzheimer’s disease. Curr. Alzheimer Res.5(2), 165–171 (2008).
   Google Scholar
• Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE. Toxicity of various amyloid β peptide species in cultured human blood–brain barrier endothelial cells: increased toxicity of dutch-type mutant. J. Neurosci. Res.60(6), 804–810 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Rivest AJ et al. The Alzheimer’s Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA99(18), 11830–11835 (2002).
   PubMed Web of Science ®Google Scholar
• Stromer T, Serpell LC. Structure and morphology of the Alzheimer’s amyloid fibril. Microsc. Res. Tech.67(3–4), 210–217 (2005).
   Google Scholar
• Cirrito JR, May PC, O’Dell MA et al.In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci.23(26), 8844–8853 (2003).
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Yamada KA, Finn MB et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron48(6), 913–922 (2005).
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Kang JE, Lee J et al. Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron58(1), 42–51 (2008).
   Google Scholar
• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6(8), 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Hsia AY, Masliah E, McConlogue L et al. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl Acad. Sci. USA96(6), 3228–3233 (1999).
   PubMed Web of Science ®Google Scholar
• Chapman PF, White GL, Jones MW et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci.2(3), 271–276 (1999).
   PubMed Web of Science ®Google Scholar
• Li QX, Maynard C, Cappai R et al. Intracellular accumulation of detergent-soluble amyloidogenic A β fragment of Alzheimer’s disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem.72(6), 2479–2487 (1999).
   Google Scholar
• Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res.840(1–2), 23–35 (1999).
   Google Scholar
• Giacchino J, Criado JR, Games D, Henriksen S. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res.876(1–2), 185–190 (2000).
   Google Scholar
• Wirths O, Multhaup G, Czech C et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett.306(1–2), 116–120 (2001).
   PubMed Web of Science ®Google Scholar
• Oddo S, Caccamo A, Shepherd JD et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron39(3), 409–421 (2003).
   PubMed Web of Science ®Google Scholar
• Ingelsson M, Fukumoto H, Newell KL et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology62(6), 925–931 (2004).
   PubMed Web of Science ®Google Scholar
• Robbins TW, Elliott R, Sahakian BJ. Neuropsychology – dementia and affective disorders. Br. Med. Bull.52(3), 627–643 (1996).
   PubMedGoogle Scholar
• Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol.163(2), 495–529 (2000).
   PubMed Web of Science ®Google Scholar
• Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol.68(3), 209–245 (2002).
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL 3rd. Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl.), 202(1–3), 15–36 (2009).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science298(5594), 789–791 (2002).
   PubMed Web of Science ®Google Scholar
• Arancio O, Zhang HP, Chen X et al. RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J.23(20), 4096–4105 (2004).
   PubMed Web of Science ®Google Scholar
• Origlia N, Righi M, Capsoni S et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J. Neurosci.28(13), 3521–3530 (2008).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Entorhinal–hippocampal interaction in mnestic disorders. Hippocampus3, 239–246 (1993).
   Google Scholar
• Witter MP. Organization of the entorhinal–hippocampal system: a review of current anatomical data. Hippocampus3, 33–44 (1993).
   PubMed Web of Science ®Google Scholar
• Suzuki WA, Amaral DG. Functional neuroanatomy of the medial temporal lobe memory system. Cortex40(1), 220–222 (2004).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol.1(3), 213–216 (1991).
   PubMed Web of Science ®Google Scholar
• Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature361(6407), 31–39 (1993).
   PubMed Web of Science ®Google Scholar
• Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science313(5790), 1093–1097 (2006).
   PubMed Web of Science ®Google Scholar
• Lambert MP, Barlow AK, Chromy BA et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA95(11), 6448–6453 (1998).
   PubMed Web of Science ®Google Scholar
• Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid β-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem.77(3), 354–371 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature416(6880), 535 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao D, Watson JB, Xie CW. Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J. Neurophysiol.92(5), 2853–2858 (2004).
   Google Scholar
• Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci.24(13), 3370–3378 (2004).
   PubMedGoogle Scholar
• Walsh DM, Townsend M, Podlisny MB et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci.25(10), 2455–2462 (2005).
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li S, Mehta TH et al. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med.14(8), 837–842 (2008).
   PubMed Web of Science ®Google Scholar
• Snyder EM, Nong Y, Almeida CG et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci.8(8), 1051–1058 (2005).
   PubMed Web of Science ®Google Scholar
• Tyszkiewicz JP, Yan Z. β-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J. Neurophysiol.93(6), 3102–3111 (2005).
   Google Scholar
• Hsieh H, Boehm J, Sato C et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron52(5), 831–843 (2006).
   PubMed Web of Science ®Google Scholar
• Parameshwaran K, Sims C, Kanju P et al. Amyloid β-peptide Aβ(1–42) but not Aβ(1–40) attenuates synaptic AMPA receptor function. Synapse61(6), 367–374 (2007).
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature382(6593), 685–691 (1996).
   PubMed Web of Science ®Google Scholar
• Yan SD, Yan SF, Chen X et al. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med.1(7), 693–699 (1995).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta1498(2–3), 99–111 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest.108(7), 949–955 (2001).
   PubMed Web of Science ®Google Scholar
• Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer’s disease: a progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis.16(4), 833–843 (2009)
   PubMed Web of Science ®Google Scholar
• Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes50(6), 1495–1504 (2001).
   PubMed Web of Science ®Google Scholar
• Li JH, Wang W, Huang XR et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol.164(4), 1389–1397 (2004).
   PubMed Web of Science ®Google Scholar
• Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential target for Aβ-mediated cellular perturbation in Alzheimer’s disease. Curr. Mol. Med.7(8), 735–742 (2007).
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci.59(7), 1117–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett.550(1–3), 107–113 (2003).
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Brachova L et al. Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp. Neurol.171(1), 29–45 (2001).
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med.9(7), 907–913 (2003).
   PubMed Web of Science ®Google Scholar
• Mucke L, Yu GQ, McConlogue L et al. Astroglial expression of human α(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol.157(6), 2003–2010 (2000).
   Google Scholar
• Simm A, Casselmann C, Schubert A et al. Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction. Exp. Gerontol.39(3), 407–413 (2004).
   PubMedGoogle Scholar
• Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta1746(1), 18–27 (2005).
   Google Scholar
• Chaney MO, Stine WB, Kokjohn TA et al. RAGE and amyloid β interactions: atomic force microscopy and molecular modelling. Biochim. Biophys. Acta1741(1–2), 199–205 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci.5(3), 173–183 (2004).
   PubMed Web of Science ®Google Scholar
• Costa M, Marchi M, Cardarelli F et al. Dynamic regulation of ERK2 nuclear translocation and mobility in living cells. J. Cell Sci.119(23), 4952–4963 (2006).
   PubMed Web of Science ®Google Scholar
• Marchi M, D’Antoni A, Formentini I et al. The N-terminal domain of ERK1 accounts for the functional differences with ERK2. PLoS One3(12), e3873 (2008).
   PubMedGoogle Scholar
• Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn. Mem.8(1), 11–19 (2001).
   PubMed Web of Science ®Google Scholar
• Mazzucchelli C, Vantaggiato C, Ciamei A et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron34(5), 807–820 (2002).
   PubMedGoogle Scholar
• Aouadi M, Binetruy B, Caron L, Le Marchand-Brustel Y, Bost F. Role of MAPKs in development and differentiation: lessons from knockout mice. Biochimie88(9), 1091–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol.14(3), 311–317 (2004).
   PubMed Web of Science ®Google Scholar
• Costa RM, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J. Child. Neurol.17(8), 622–651 (2002).
   PubMedGoogle Scholar
• Kanterewicz BI, Urban NN, McMahon DB et al. The extracellular signal-regulated kinase cascade is required for NMDA receptor-independent LTP in area CA1 but not area CA3 of the hippocampus. J. Neurosci.20(9), 3057–3066 (2000).
   Google Scholar
• Coogan AN, O’Leary DM, O’Connor JJ. P42/44 MAP kinase inhibitor PD98059 attenuates multiple forms of synaptic plasticity in rat dentate gyrus in vitro. J. Neurophysiol.81(1), 103–110 (1999).
   Google Scholar
• Huang YY, Martin KC, Kandel ER. Both protein kinase A and mitogen-activated protein kinase are required in the amygdala for the macromolecular synthesis-dependent late phase of long-term potentiation. J. Neurosci.20(17), 6317–6325 (2000).
   PubMed Web of Science ®Google Scholar
• Schafe GE, Atkins CM, Swank MW et al. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J. Neurosci.20(21), 8177–8187 (2000).
   PubMed Web of Science ®Google Scholar
• Di Cristo G, Berardi N, Cancedda L et al. Requirement of ERK activation for visual cortical plasticity. Science292(5525), 2337–2340 (2001).
   Google Scholar
• English JD, Sweatt JD. Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J. Biol. Chem.271(40), 24329–24332 (1996).
   PubMed Web of Science ®Google Scholar
• Impey S, Obrietan K, Wong ST et al. Cross talk between ERK and PKA is required for Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron21(4), 869–883 (1998).
   PubMed Web of Science ®Google Scholar
• Pages G, Guerin S, Grall D et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science286(5443), 1374–1377 (1999).
   PubMed Web of Science ®Google Scholar
• Samuels IS, Karlo JC, Faruzzi AN et al. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J. Neurosci.28(27), 6983–6995 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell110(4), 443–455 (2002).
   PubMed Web of Science ®Google Scholar
• Webster B, Hansen L, Adame A et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol.65(2), 142–151 (2006).
   Google Scholar
• Dineley KT, Westerman M, Bui D et al. B-amyloid activates the mitogen-activated protein kinase cascade via hippocampal a7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s disease. J. Neurosci.21(12), 4125–4133 (2001).
   PubMed Web of Science ®Google Scholar
• Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ. Mol. Cell. Neurosci.9(3), 220–234 (1997).
   PubMedGoogle Scholar
• Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar β-amyloid in mature hippocampal neurons. J. Neurochem.74(1), 125–133 (2000).
   PubMed Web of Science ®Google Scholar
• Chong YH, Shin YJ, Lee EO et al. ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem.281(29), 20315–20325 (2006).
   PubMed Web of Science ®Google Scholar
• Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther.319(3), 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Stanciu M, Wang Y, Kentor R et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem.275(16), 12200–12206 (2000).
   PubMed Web of Science ®Google Scholar
• Townsend M, Mehta T, Selkoe DJ. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem.282(46), 33305–33312 (2007).
   PubMed Web of Science ®Google Scholar
• Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-β oligomer neurotoxicity. J. Neurosci.28(20), 5149–5158 (2008).
   PubMed Web of Science ®Google Scholar
• Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J.16(12), 3563–3571 (1997).
   PubMedGoogle Scholar
• Cuenda A, Cohen P, Buee-Scherrer V, Goedert M. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J.16(2), 295–305 (1997).
   PubMed Web of Science ®Google Scholar
• Kuma Y, Sabio G, Bain J et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem.280(20), 19472–19479 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen PS, Schmidtmayerova H, Dennis J et al. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med.3(5), 339–346 (1997).
   PubMed Web of Science ®Google Scholar
• Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev.81(2), 807–869 (2001).
   PubMed Web of Science ®Google Scholar
• Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta1773(8), 1358–1375 (2007).
   PubMed Web of Science ®Google Scholar
• Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3–CA1 synapses. Nat. Neurosci.3(11), 1107–1112 (2000).
   PubMedGoogle Scholar
• Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science270(5240), 1326–1331 (1995).
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Morooka T, Shimohama S et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem.272(30), 18518–18521 (1997).
   PubMed Web of Science ®Google Scholar
• Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci.23(5), 1605–1611 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial proinflammatory cytokine IL-1β production. Neurobiol. Aging25(4), 431–439 (2004).
   PubMed Web of Science ®Google Scholar
• Culbert AA, Skaper SD, Howlett DR et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits proinflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem.281(33), 23658–23667 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu X, Mei M, Lee HG et al. P38 activation mediates amyloid-β cytotoxicity. Neurochem. Res.30(6–7), 791–796 (2005).
   Google Scholar
• Troy CM, Rabacchi SA, Xu Z et al. β-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J. Neurochem.77(1), 157–164 (2001).
   PubMed Web of Science ®Google Scholar
• Coogan AN, O’Neill LA, O’Connor JJ. The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1β on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience93(1), 57–69 (1999).
   PubMed Web of Science ®Google Scholar
• Kelly A, Vereker E, Nolan Y et al. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 β on long term potentiation in rat dentate gyrus. J. Biol. Chem.278(21), 19453–19462 (2003).
   PubMed Web of Science ®Google Scholar
• Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem.275, 7395–7402 (2000).
   PubMed Web of Science ®Google Scholar
• Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA98, 13681–13686 (2001).
   PubMed Web of Science ®Google Scholar
• Munoz L, Ranaivo HR, Roy SM et al. A novel p38 α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model. J. Neuroinflam.4(21), 1–14 (2007).
   Google Scholar
• Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem.269(13), 9889–9897 (1994).
   PubMed Web of Science ®Google Scholar
• Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature353(6345), 670–674 (1991).
   PubMed Web of Science ®Google Scholar
• Derijard B, Hibi M, Wu IH et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell76(6), 1025–1037 (1994).
   PubMed Web of Science ®Google Scholar
• Yang D, Tournier C, Wysk M et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc. Natl Acad. Sci. USA94(7), 3004–3009 (1997).
   PubMedGoogle Scholar
• Kallunki T, Su B, Tsigelny I et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev.8(24), 2996–3007 (1994).
   PubMed Web of Science ®Google Scholar
• Gupta S, Barrett T, Whitmarsh AJ et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J.15(11), 2760–2770 (1996).
   PubMed Web of Science ®Google Scholar
• Chang JS, Wendt T, Qu W et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res.102(8), 905–913 (2008).
   PubMed Web of Science ®Google Scholar
• Chen JT, Lu DH, Chia CP et al. Impaired long-term potentiation in c-Jun N-terminal kinase 2-deficient mice. J. Neurochem.93(2), 463–473 (2005).
   Google Scholar
• Carletti R, Tacconi S, Bettini E, Ferraguti F. Stress activated protein kinases, a novel family of mitogen-activated protein kinases, are heterogeneously expressed in the adult rat brain and differentially distributed from extracellular-signal-regulated protein kinases. Neuroscience69(4), 1103–1110 (1995).
   PubMedGoogle Scholar
• Kumagae Y, Zhang Y, Kim OJ, Miller CA. Human c-Jun N-terminal kinase expression and activation in the nervous system. Brain Res. Mol. Brain Res.67(1), 10–17 (1999).
   PubMedGoogle Scholar
• Mielke K, Herdegen T. JNK and p38 stresskinases – degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol.61(1), 45–60 (2000).
   PubMed Web of Science ®Google Scholar
• Curran BP, Murray HJ, O’Connor JJ. A role for c-Jun N-terminal kinase in the inhibition of long-term potentiation by interleukin-1β and long-term depression in the rat dentate gyrus in vitro. Neuroscience118(2), 347–357 (2003).
   PubMed Web of Science ®Google Scholar
• Li XM, Li CC, Yu SS et al. JNK1 contributes to metabotropic glutamate receptor-dependent long-term depression and short-term synaptic plasticity in the mice area hippocampal CA1. Eur. J. Neurosci.25(2), 391–396 (2007).
   Google Scholar
• Xu X, Raber J, Yang D, Su B, Mucke L. Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. Proc. Natl Acad. Sci. USA94(23), 12655–12660 (1997).
   PubMed Web of Science ®Google Scholar
• Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson’s diseases therapy. Curr. Drug Targets CNS Neurol. Disord.4(1), 63–67 (2005).
   PubMedGoogle Scholar
• Silva RM, Kuan CY, Rakic P, Burke RE. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson’s disease. Mov. Disord.20(6), 653–664 (2005).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Morphological criteria for the recognition of Alzheimer’s disease and the distribution pattern of cortical changes related to this disorder. Neurobiol. Aging15(3), 355–380 (1994).
   PubMed Web of Science ®Google Scholar
• Pei JJ, Braak E, Braak H et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer’s disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis.3(1), 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Shoji M, Iwakami N, Takeuchi S et al. JNK activation is associated with intracellular β-amyloid accumulation. Brain Res. Mol. Brain Res.85(1–2), 221–233 (2000).
   PubMedGoogle Scholar
• Morishima Y, Gotoh Y, Zieg J et al. B-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci.21(19), 7551–7560 (2001).
   PubMed Web of Science ®Google Scholar
• Jang JH, Surh YJ. β-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann. NY Acad. Sci.973, 228–236 (2002).
   PubMed Web of Science ®Google Scholar
• Wei W, Norton DD, Wang X, Kusiak JW. Aβ 17–42 in Alzheimer’s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain125(Pt 9), 2036–2043 (2002).
   PubMed Web of Science ®Google Scholar
• Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the β-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem. J.371(Pt 3), 789–798 (2003).
   Google Scholar
• Minogue AM, Schmid AW, Fogarty MP et al. Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-β on long term potentiation and cell death in hippocampus: a role for interleukin-1b? J. Biol. Chem.278(30), 27971–27980 (2003).
   Google Scholar
• Bell KA, O’Riordan KJ, Sweatt JD, Dineley KT. MAPK recruitment by β-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem.91(2), 349–361 (2004).
   Google Scholar
• Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature405(6784), 354–360 (2000).
   PubMed Web of Science ®Google Scholar
• Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell.4(4), 521–533 (2003).
   PubMed Web of Science ®Google Scholar
• Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-κB and AP-1 coregulation of COX-2 expression by S100B, IL-1β and TNF-α. Neurobiol. Aging (2008).
   Google Scholar
• Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA. Modulation of amyloid-β-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J. Neurochem.103(3), 914–926 (2007).
   Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J. Alzheimers Dis.6(6 Suppl.), S61–S74 (2004).
   Google Scholar
• Klyubin I, Wang Q, Reed MN et al. Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol. Aging (2009) (Epub ahead of print).
   Google Scholar
• Lazarov O, Marr RA. Neurogenesis and Alzheimer’s disease: at the crossroads. Exp. Neurol. DOI: 10.1016/j.expneurol.2009.08.009 (2009) (Epub ahead of print).
   Google Scholar
• Wang JM, Irwin RW, Liu L, Chen S, Brinton RD. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr. Alzheimer Res.4(5), 510–517 (2007).
   PubMed Web of Science ®Google Scholar
• Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer’s disease: alloprenanaolone as a proof of concept neurogenic agent. Curr. Alzheimer Res.3(3), 185–190 (2006).
   PubMedGoogle Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol.8(2), 101–112 (2007).
   PubMed Web of Science ®Google Scholar
• Tomita T. At the frontline of Alzheimer’s disease treatment: γ-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch. Pharmacol.377(4–6), 295–300 (2008).
   PubMed Web of Science ®Google Scholar
• Puzzo D, Privitera L, Leznik E et al. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci.28(53), 14537–14545 (2008).
   PubMed Web of Science ®Google Scholar
• Federoff HJ. Development of vaccination approaches for the treatment of neurological diseases. J. Comp. Neurol.515(1), 4–14 (2009).
   Google Scholar
• Giuffrida ML, Caraci F, Pignataro B et al. β-amyloid monomers are neuroprotective. J. Neurosci.29(34), 10582–10587 (2009).
   PubMed Web of Science ®Google Scholar
• Atwood CS, Obrenovich ME, Liu T et al. Amyloid-β: a chameleon walking two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res. Brain Res. Rev.46(1), 118–120 (2003).
   Google Scholar
• Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity. Exp. Gerontol.39(11–12), 1661–1667 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu X, Rottkamp CA, Hartzler A et al. Activation of MKK6, an upstream activator of p38, in Alzheimer’s disease. J. Neurochem.79(2), 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Giovannini MG, Scali C, Prosperi C et al. β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis.11, 257–274 (2002).
   PubMed Web of Science ®Google Scholar
• Hensley K, Floyd RA, Zheng NY et al. P38 kinase is activated in the Alzheimer’s disease brain. J. Neurochem.72, 2053–2058 (1999).
   PubMed Web of Science ®Google Scholar
• Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp. Neurol.183, 394–405 (2003).
   PubMed Web of Science ®Google Scholar
• Swatton JE, Sellers LA, Faull RL, Holland A, Iritani S, Bahn S. Increased MAP kinase activity in Alzheimer’s and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci.19, 2711–2719 (2004).
   PubMed Web of Science ®Google Scholar
• Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J. Neurosci.22, 3376–3385 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer’s disease, tauopathies and APP transgenic mice. Neurotox. Res.6, 469–475 (2004).
   Google Scholar
• Webster J, Andrews R, Shen J et al. Small-molecule inhibitors of the receptor for advanced glycation end-products (RAGE) are an effective therapy in animal models of Alzheimer’s disease. Program and abstracts of the ICAD 2008: Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008.
   Google Scholar
• Sabbagh MN, Bell J, Agro A, Aisen P, Galasko D. An oral antagonist of the receptor for advanced glycation end-products (RAGE) is safe and well-tolerated in the treatment of Alzheimer’s disease: Results from a Phase II study. Program and abstracts of the ICAD 2008: Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008
   Google Scholar